Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: a pilot double blind transdermal nicotine positron emission tomography study
- PMID: 8976498
- DOI: 10.1007/BF01875368
Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: a pilot double blind transdermal nicotine positron emission tomography study
Abstract
Nicotinic receptor dysfunction and impaired semantic memory occur early in Alzheimer's disease patients (AD). Previous research implied that nicotine's ability to enhance alertness, arousal, and cognition in a number of nonclinical populations was a function of its ability to stimulate CNS nicotinic cholinergic receptors. In this study it was hypothesized that transdermal administration of nicotine would increase both regional cerebral glucose metabolism (rCMRglc) and semantic memory (as assessed by verbal fluency). Two mild AD and two elderly controls underwent positron emission tomography scanning during a double blind nicotinic agonist verbal fluency challenge procedure. rCMRglc increases occurred in both AD patients, but not controls. In the two AD patients, verbal fluency scores increased by an average of 17%. One elderly control's verbal fluency increased, and the other decreased. These findings suggest that nicotine's effect on metabolism and verbal fluency is due to its ability to stimulate the cholinergic system.
Similar articles
-
Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety.Pharmacol Biochem Behav. 1995 Jun-Jul;51(2-3):509-14. doi: 10.1016/0091-3057(95)00043-v. Pharmacol Biochem Behav. 1995. PMID: 7667377 Clinical Trial.
-
The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease.Dementia. 1996 Jan-Feb;7(1):47-52. doi: 10.1159/000106852. Dementia. 1996. PMID: 8788082 Clinical Trial.
-
Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease.Psychopharmacology (Berl). 1999 Apr;143(2):158-65. doi: 10.1007/s002130050931. Psychopharmacology (Berl). 1999. PMID: 10326778 Clinical Trial.
-
PET studies and cholinergic therapy in Alzheimer's disease.Rev Neurol (Paris). 1999;155 Suppl 4:S53-63. Rev Neurol (Paris). 1999. PMID: 10637939 Review.
-
Nicotine's effect on neural and cognitive functioning in an aging population.Aging Ment Health. 2002 May;6(2):129-38. doi: 10.1080/13607860220126808. Aging Ment Health. 2002. PMID: 12028881 Review.
Cited by
-
Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer's disease.J Chem Neuroanat. 2011 Oct;42(2):111-7. doi: 10.1016/j.jchemneu.2011.02.004. Epub 2011 Mar 17. J Chem Neuroanat. 2011. PMID: 21397006 Free PMC article.
-
Selective excitation of subtypes of neocortical interneurons by nicotinic receptors.J Neurosci. 1999 Jul 1;19(13):5228-35. doi: 10.1523/JNEUROSCI.19-13-05228.1999. J Neurosci. 1999. PMID: 10377334 Free PMC article.
-
Recent developments in the drug treatment of Alzheimer's disease.Drugs Aging. 1999 May;14(5):359-73. doi: 10.2165/00002512-199914050-00004. Drugs Aging. 1999. PMID: 10408736 Review.
-
Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.Biochem Pharmacol. 2007 Oct 15;74(8):1192-201. doi: 10.1016/j.bcp.2007.07.015. Epub 2007 Jul 17. Biochem Pharmacol. 2007. PMID: 17714692 Free PMC article. Review.
-
Nicotine improves delayed recognition in schizophrenic patients.Psychopharmacology (Berl). 2004 Jul;174(3):334-40. doi: 10.1007/s00213-003-1764-8. Epub 2004 Mar 2. Psychopharmacology (Berl). 2004. PMID: 14997272 Clinical Trial.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical